Saturday, October 06, 2018 11:20:19 AM
https://fintel.io/so/us/avxl?d=2015-12-31
And when these institutions increased positions in first quarter of 2017 most of the volume was in the range of $5 - $6 with the high of $6.50 reached just before ParkWest announced 5% holdings:
previous current
2017-05-12 13F-HR BlackRock Inc. 1,344 1,605,252 119,338.39 5 9,214 184,180.00
2017-04-11 13F-HR BANK OF MONTREAL /CAN/ 2,000 77,000 3,750.00 8 442 5,425.00
2017-05-15 13F-HR BARCLAYS PLC 549 14,280 2,501.09 2 81 3,950.00
2017-05-15 13F-HR DEUTSCHE BANK AG\ 18,371 58,340 217.57 72 334 363.89
2017-05-10 13F-HR GROUP ONE TRADING, L.P. Put 51,000 119,500 134.31 202 686 239.60
2017-05-12 13F-HR CITADEL ADVISORS LLC Call 13,300 29,700 123.31 53 170 220.75
2017-05-15 13F-HR SUSQUEHANNA INTNL GROUP, LLP Call 16,500 35,200 113.33 65 202 210.77
2017-04-11 13F-HR BANK OF MONTREAL /CAN/ Put 36,100 75,000 107.76 131 431 229.01
2017-04-11 13F-HR Cutler Group LP Put 31,600 62,800 98.73 42 36 -14.29
2017-05-15 13F-HR Park West Asset Mgmt LLC 1,500,000 2,962,090 97.47 5,940 17,002 186.23
2017-05-15 13F-HR PRICE T ROWE ASSOC. /MD/ 29,785 53,285 78.90 118 306 159.32
https://fintel.io/so/us/avxl?d=2017-03-31
And when a few institutions who were holding Russel index fund shares sold and offered size the price also went up...
IMO - this is proof that institutions are unable to acquire size without pushing the stock price up. They can not " get as many shares as they like between 2.50 and 3.50". In fact most of their shares must have been acquired at $3.50 or more.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM

